Ukoyisa i-Diffuse Large B-Cell Lymphoma nge-Bioocus Dual CAR-T Therapy

Imvelaphi yesigulane

URodney, umntu ohlala ephikelelayo ovela phesheya, wafunyaniswa ene-Diffuse Large B-Cell Lymphoma (DLBCL), uhlobo olubi lwe-non-Hodgkin lymphoma. Kwiminyaka engama-68 ubudala, wafuna iindlela zonyango eziphambili emva kokuba unyango oluqhelekileyo lungazange luphumelele. Ethunyelwe kwiziko lethu elisebenzisana nathi kwiSibhedlele soMhlaza saseTianjin, uRodney wabhalisa kwi-Bioocus's dual CAR-T therapy protocol phantsi kwenombolo yonyango P1549. Olu nyango lujolise kwii-antigen ze-CD19 kunye ne-CD20 kwiiseli zomhlaza, lubonelela ngohlaselo olunamacala amabini ukuphucula ukusebenza kakuhle kunye nokunciphisa umngcipheko wokubuyela umva.

Uhambo Lonyango

Unyango lukaRodney lwaqala ngoSeptemba 2025 ngokufakwa kweeseli ze-CAR-T ezizii-autologous ezenzelwe ukuvelisa ii-receptors ze-chimeric antigen ze-CD19 kunye ne-CD20. Le nkqubo yayiquka ukuqokelela isampuli yakhe yegazi elingaphandle (PB), ukuyicubungula ukuze kwenziwe iiseli ze-CAR-T ezenzelwe wena, kunye nokufaka idosi ehambelana neemfuno zakhe. Emva kokufakwa, inkqubela yakhe yajongwa ngokusondeleyo ngovavanyo lwegazi olulandelelanayo kwiintsuku ezibalulekileyo zokulandelela: Usuku lwesi-4 (D4), Usuku lwesi-7 (D7), kunye noSuku lwe-10 (D10).

• D4 (nge-12 kaSeptemba, 2025):Ukufunyanwa kokuqala kubonise ukubakho kweeseli ze-CAR-T okuncinci, kunye neeseli ze-CD19+ CAR-T kwi-0.50% yeeseli ze-CD3+ T (ixabiso elipheleleyo: 6.04 × 10^6/L) kunye neeseli ze-CD20+ CAR-T kwi-0.41% (ixabiso elipheleleyo: 4.96 × 10^6/L). Eli nqanaba lokuqala libonise ukufakelwa ngempumelelo.
• D7 (nge-15 kaSeptemba, 2025):Ukwanda kukhawulezisiwe, iiseli ze-CD19+ CAR-T zinyuka ziye kwi-1.68% (ixabiso elipheleleyo: 1.40 × 10^7/L) kunye neeseli ze-CD20+ CAR-T ziye kwi-1.63% (ixabiso elipheleleyo: 1.36 × 10^7/L), nto leyo ebonisa ukwanda okuqinileyo.
• D10 (nge-18 kaSeptemba, 2025):Kubonwe ukwanda okukhulu, apho iiseli ze-CD19+ CAR-T zifikelela kwi-31.43% yeeseli ze-CD3+ T (ixabiso elipheleleyo: 3.13 × 10^8/L) kunye neeseli ze-CD20+ CAR-T kwi-32.74% (ixabiso elipheleleyo: 3.26 × 10^8/L). Uhlalutyo lwe-subset lubonise ukusasazwa okulinganayo kwiiseli ze-CD4+ kunye ne-CD8+ T, kunye nokubalwa kweeseli ze-T kwi-2.9 × 10^9/L, kuquka neeseli ze-CD3+ T ezingama-34.35%.

Kuyo yonke inkqubo yokubeka esweni, iprofayili yomzimba kaRodney ibonise utshintsho oluhle, olufana neeseli ze-T ezinobungozi obuphezulu (CD3+CD8+ kwi-69.56%), nto leyo egxininisa amandla onyango okukhuthaza amajoni omzimba akhe ukuba alwe ne-lymphoma.

Iziphumo Ezibalaseleyo

Ngo-D10, ukukhula okukhulu kwiiseli ze-CAR-T—ngaphezulu kokwanda okuphindwe ka-500 kwinani elipheleleyo ukusuka kwi-D4—kwabonisa umsebenzi onamandla wonyango wokulwa nethumba. Olu lwando lukhawulezileyo luphawu lonyango lwe-CAR-T oluphumeleleyo, oluhlala luhambelana nokukhululwa okunzulu nokuhlala ixesha elide kwizigulane ze-DLBCL. URodney walunyamezela kakuhle unyango, kungekho ngxaki zinkulu zixeliweyo kwisigaba sokujonga. Ityala lakhe libonisa indlela ye-Bioocus ye-CAR-T ephindwe kabini, efikelele kwimpendulo epheleleyo ephezulu (CR) kunye namazinga okuphendula ngokubanzi (ORR) kulo lonke iqela lethu lezigulane zehlabathi.